+ All Categories
Home > Health & Medicine > Global Pharmaceutical Contract Manufacturing Market

Global Pharmaceutical Contract Manufacturing Market

Date post: 07-May-2015
Category:
Upload: aiswariya-chidambaram
View: 4,295 times
Download: 3 times
Share this document with a friend
Description:
This research service provides an in-depth analysis of the global pharmaceutical contract manufacturing market with particular focus on the finished dose formulations such as solid, liquid and semi-solid, and injectable dose formulations. Segment analysis, trends and revenue forecast for the global, U.S. and European regions have been provided in detail. Strategic recommendations for the success of market participants have also been discussed.
36
Global Pharmaceutical Contract Manufacturing Market Injectable Dose Formulations Will Likely Spur the Growth of CMOs NC04-52 August 2013
Transcript
Page 1: Global Pharmaceutical Contract Manufacturing Market

Global Pharmaceutical Contract Manufacturing Market Injectable Dose Formulations Will Likely Spur the Growth of CMOs

NC04-52

August 2013

Page 2: Global Pharmaceutical Contract Manufacturing Market

Research Team

Aiswariya Chidambaram Senior Research Analyst

Life Sciences

(9144) 6160-4249

[email protected]

Lead Analyst

Page 3: Global Pharmaceutical Contract Manufacturing Market

3 NC04-52

Scope and Segmentation

Geographic coverage Global: United States, Europe (Germany, United Kingdom, France, Italy,

Spain, Scandinavia, and Benelux), and Rest of World (ROW)

Study period 2009–2017

Base year 2012

Forecast period 2013–2017

Monetary unit US Dollars

Conversion rate €1 = $1.31

Source: Frost & Sullivan

Page 4: Global Pharmaceutical Contract Manufacturing Market

4 NC04-52

Market Segmentation

The pharmaceutical contract manufacturing market can be broadly divided into 3 main segments: solid

dose formulations, liquid and semi-solid dose formulations, and injectable dose formulations.

• Solid dose formulations comprise basic (tablets and capsules) and advanced (controlled-release), fast-

dissolving, and soft-gel, which are multi-active pharmaceutical ingredient (API) oral finished dose

formulations.

• Liquid and semi-solid dose formulations include nasal, nebulized, ophthalmic, otic, and topical

formulations, including sterile and non-sterile preparations.

• Injectable dose formulations are sterile preparations, including small- and large-volume parenterals.

Small-volume parenterals are of 2 types: cytotoxic and non-cytotoxic.

Solid Dose Formulations Liquid and Semi-solid Dose

Formulations

Total Pharmaceutical Contract Manufacturing Market

Total Pharmaceutical Contract Manufacturing Market: Market Segmentation, Global, 2012

Injectable Dose

Formulations

Market Segmentation

Source: Frost & Sullivan

Page 5: Global Pharmaceutical Contract Manufacturing Market

5 NC04-52

Segment Lifecycle Analysis

Injectable Dose Formulations

Maturity Development Growth Decline Time

Se

gm

en

t V

alu

e

Solid Dose Formulations

Injectable dose formulations is the

fastest growing segment, with a

projected growth rate of 12.2% in

2012, which is higher than the

overall pharmaceutical contract

manufacturing market. Increased

focus on cytotoxics, lyophilised

prefilled syringes, and

reformulation of existing products

is expected to drive the

remarkable success of injectables.

The liquid and semi-solid dose

formulations segment is

declining because of storage

and transportation issues, with

the major target group being the

paediatric population. Minimal

R&D is also carried out in this

segment.

Solid dose formulations is the

largest segment of the global

pharmaceutical contract

manufacturing market. Growth in

this segment is primarily attributed

to lower cost, ease of

manufacturing, patient compliance,

and the patent cliff.

Note: Bubble size represents market size.

Liquid and Semi-solid

Dose Formulations

Total Pharmaceutical Contract Manufacturing Market: Segment Lifecycle Analysis, Global, 2012

Source: Frost & Sullivan

Page 6: Global Pharmaceutical Contract Manufacturing Market

6 NC04-52

Market Engineering Measurements

Market Stage

Growth

Market Revenue

$13.43 B

(2012)

Market

Penetration

Medium

(2012)

Market Nature

Fragmented

Market Size for

Last Year of

Study Period

$18.49 B

(2017)

Base Year

Market Growth

Rate

5.9%

Compound

Annual Growth

Rate

6.6%

(CAGR, 2012 - 2017)

Customer Price

Sensitivity

9

(scale:1 [low] to 10 [High])

Degree of

Technical

Change

8

(scale:1 [low] to 10 [High])

For a tabular version click here.

Market

Concentration

23.0%

Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements,

Global, 2012 Market Overview

(% of market share held by top

3 companies)

Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan

Stable Increasing Decreasing

Page 7: Global Pharmaceutical Contract Manufacturing Market

7 NC04-52

Number of

Competitors

Nearly 450

(active market competitors in

2012)

Number of

Generic

Manufacturers

High

(none, low, medium, high)

Market Engineering Measurements (continued)

Competitor Overview

Number of

Companies that

Entered

< 10

(2012)

Additional Key Metrics

Average

Product

Development

Time

5–10 years

Stable Increasing Decreasing

Industry

Capacity

Utilisation Rate

45.0%

(2012)

Note: All figures are rounded. The base year is 2012. Source: Frost & Sullivan

Page 8: Global Pharmaceutical Contract Manufacturing Market

8 NC04-52

CEO’s Perspective

2

The pharmaceutical contract manufacturing

market is highly fragmented, and

consolidation is required to improve

profitability.

3

Thirty percent of existing participants could

exit the market due to pricing pressure and

low profit margins, mainly in the liquid and

semi-solid dose formulations segment.

4

Capturing projects at the early life-cycle

stage of products and a risk-sharing business

model can help build long-term strategic

relationships.

1

Lyophilisation and manufacturing of sterile

products such as cytotoxics will likely be

areas of growth potential, given the demand

for oncology and high-potency drugs.

Page 9: Global Pharmaceutical Contract Manufacturing Market

9 NC04-52

Key Findings

• In 2012, the global pharmaceutical contract manufacturing market generated $13.43 billion in revenue.

The forecast shows a compound annual growth rate (CAGR) of 6.6% from 2012 to 2017.

o The injectable dose formulations segment will likely be the primary growth driver for outsourcing

throughout the forecast period.

• In 2012, solid dose formulations was the largest segment, constituting 49.8% of the total pharmaceutical

contract manufacturing market, and is projected to grow at a CAGR of 3.4% from 2012 to 2017.

o Generics will likely be a key growth driver for the solid dose formulations segment; however, this

segment will likely lose shares to the injectable dose formulations segment because of big pharma’s

shift in focus from small molecules to large molecules.

• Injectable dose formulations is the fastest growing segment and is projected to register a robust CAGR

of 13% from 2012 to 2017.

o Key growth drivers include increased pharmaceutical and biotechnological focus on complex disease

areas, trends in disease control, growth in emerging markets, the pharmaceutical patent cliff (several

blockbuster drugs losing patent protection), and reformulation of existing products.

o The major growth contributor is expected to be cytotoxics as both cancer research and the

development of new cancer therapies are driving growth in this area.

Source: Frost & Sullivan

Page 10: Global Pharmaceutical Contract Manufacturing Market

10 NC04-52

• The liquid and semi-solid dose formulations segment is quite mature and expected to experience a

relatively lower CAGR of 2.5% from 2012 to 2017.

o Decreasing demand for liquid dose formulations is primarily attributed to transportation, storage, and

packaging issues associated with these formulations as well as lower returns compared to injectable

dose formulations manufacturing.

o The sterile liquid and semi-solid dose preparations, particularly nasal ophthalmic dose formulations,

are expected to experience strong growth; however, these preparations currently constitute a very

small segment of the market.

• Because of big pharma’s increased outsourcing, the pharmaceutical contract manufacturing market is

expected to show consistent growth. CMOs are striving to provide greater value proposition for clients

by engaging in the early life-cycle stage projects and establishing long-term relationships.

o To improve their value proposition to manufacturers, many CMOs are focusing on pre-clinical

development services and can transition from offering clinical services to offering commercial

manufacturing to integrate throughout the value chain of clients.

• Industry consolidation is on an increasing curve. The fragmented market nature will likely intensify

pricing pressure and drive down CMO revenues.

• Catalent Inc., Patheon Inc., and Aenova (with the acquisition of the Temmler group) are the top 3

market participants, constituting a combined share of 23% in the global pharmaceutical contract

manufacturing market.

Key Findings (continued)

Source: Frost & Sullivan

Page 11: Global Pharmaceutical Contract Manufacturing Market

11 NC04-52

Defining CMO Trends in the Future

Topic Present (2012) Future Outlook (2022)

Key Areas

Outsourced

A majority of CMOs currently outsource

development activities such as formulations,

toxicity testing, fill and finish services, and

product characterization activities.

Outsourcing of crucial operations such as upstream and downstream

processes is likely in the interest of time, cost, and efficiency.

Capacity

Utilisation

The global industry capacity utilisation rate

is nearly 45%.

The global industry capacity utilisation rate is expected to increase 55 to

60% because of several blockbuster drugs coming out of patent, new

product launches, and more plant shut downs.

Role of Venture

Capital (VC) Firms

The lack of interest from VC firms to invest

in CMO space is because of poor

profitability and an unstable economic

climate.

VC investments may solidify when the economy gains more steam.

CMOs in emerging markets could be potential targets for investments.

Industry

Consolidation

Consolidation in the form of strategic

partnerships between CMOs,

pharmaceutical and biotech companies,

drug delivery companies, and technology

providers is on an increasing curve.

There will be greater consolidation and emphasis on core dose

formulations in the global CMO market. Thirty percent of current

participants will likely exit over the next 10 years because of intense

price competition and poor profit margins, particularly in liquid and semi-

solid dose formulations.

Favored

Destinations for

Outsourcing

Currently, the United States and Europe are

major markets for outsourcing of finished

dose formulations and sterile preparations,

while Asian CMOs are preferred

destinations for APIs, intermediates, and

generics.

Given the immense cost benefits, Asian CMOs such as in India, China,

and Singapore will likely emerge as favorable destinations, particularly

for solid dose formulations.

Business Model Several CMOs focus on manufacturing

services as their core business segment.

Adherence to an integrated end-to-end business model offers value-

added services, thereby serving as a one-stop shop for customers.

How will your company meet the future needs of the industry?

Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2012 and 2022

Source: Frost & Sullivan

Page 12: Global Pharmaceutical Contract Manufacturing Market

12 NC04-52

New Market Opportunities

Unmet Needs

• An integrated, end-to-end business model on a

risk sharing basis with clients

• Instilling new capabilities and anticipating

capacity demand for careful outweighing of

benefits and risks

• Huge demand for next-generation biological

therapies such as vaccines, anti-cancer

therapies, gene therapies, specialized antibiotic

treatments, and recombinant proteins

Current Participant Strategies

• Repositioning product/service offerings to

enhance value proposition among clients and

building long-term strategic partnerships on a

risk-sharing basis

• Acquiring new capabilities and capacity

expansions by means of strategic partnerships

to fulfill global demand

• Increased focus on niche specialties such as

aseptic manufacturing of injectable dose

formulations to reap higher profit margins

Source: Frost & Sullivan

Page 13: Global Pharmaceutical Contract Manufacturing Market

13 NC04-52

Key Companies to Watch

Patheon Inc.

• Patheon provides services to

more than 300 clients,

including the world’s 20

largest pharmaceutical

companies, 9 of the 20 largest

specialty pharmaceutical

companies, and 10 of the 20

largest biotech companies.

• Patheon has a strong track

record in the solid dose

formulations segment, with

one of the highest number of

solid dose drugs worldwide.

• Patheon has one of the

highest number of FDA new

drug approvals compared to

most other CMOs.

Aenova

• Aenova is one of the world’s

largest full-service providers

in the solid dose formulations

segment, with cutting-edge

technologies in the

production of a wide range of

tablets and capsules.

• Aenova experienced a

significant increase in market

shares after acquiring the

Temmler Group.

• Aenova acquired new

capabilities in products (liquid

and semi-solid dose

formulations) and services

(manufacturing of clinical trial

materials, logistics,

distribution, and licensing).

Baxter BioPharma Solutions

• Baxter is well known for its

proven expertise in parenteral

dose manufacturing, with

more than 1 billion sterile units

manufactured per year.

• Baxter was the first company

to introduce premixed drugs in

IV containers and the first

company to package its drugs

in IV containers.

• Baxter has an established

physician user base

worldwide, providing valuable

distribution channels to

expedite new product

launches combined with

strong sales and marketing

support services.

For additional information on companies, click here. Source: Frost & Sullivan

Page 14: Global Pharmaceutical Contract Manufacturing Market

14 NC04-52

2 Given the highly fragmented market nature and intense competition, CMO providers

will likely adopt a differentiation strategy to reposition themselves among clients.

3

Investments and capacity expansions in the injectable dose formulations segment,

particularly cytotoxics manufacturing, are expected as they are anticipated to be the

most significant sources of revenue for the pharmaceutical contract manufacturing

industry.

1 Consolidation and an emphasis on core dose formulations will likely continue in the

pharmaceutical contract manufacturing market. Thirty percent of the current market

participants will likely exit over the next 10 years.

Executive Summary—3 Big Predictions

Source: Frost & Sullivan

Page 15: Global Pharmaceutical Contract Manufacturing Market

15 NC04-52

Contents

Section Slide Number

Executive Summary 25

• Scope and Segmentation 26

• Market Segmentation 27

• Key Questions This Study Will Answer 28

• Market Engineering Measurements 29

• CEO’s Perspective 31

• Key Findings 32

• Key Companies to Watch 34

• Executive Summary—3 Big Predictions 35

• The Last Word—Discussion 36

Market Overview 39

• Market Segmentation 40

• Segmentation by Manufacturing Process 41

• Segmentation by Patent Exclusivity Status 42

• Global Market Perspective 43

• Defining CMO Trends in the Future 44

Page 16: Global Pharmaceutical Contract Manufacturing Market

16 NC04-52

Contents (continued)

Section Slide Number

Competitive Playbook 45

• New Market Opportunities 46

• Key Merger, Acquisition and Partnership Assessment 48

Drivers, Restraints, and Trends—Total Pharmaceutical Contract Manufacturing Market 51

• Market Drivers 52

• Market Restraints 53

• Market Impact of Key Drivers and Restraints 54

Forecasts and Trends—Total Pharmaceutical Contract Manufacturing Market 55

• Market Engineering Measurements 56

• Forecast Assumptions 58

• Revenue Forecast 59

• Revenue Forecast Discussion 60

• Percent Revenue Forecast by Region 63

• Revenue Forecast by Region 64

• Key Market Trends 65

Page 17: Global Pharmaceutical Contract Manufacturing Market

17 NC04-52

Contents (continued)

Section Slide Number

• Key Technology Trends 72

• Market Impact of Key Trends 76

• Venture Capital Trends in CMO 77

• Segment Lifecycle Analysis 78

End-User Analysis/Demand Analysis—Total Pharmaceutical Contract Manufacturing

Market

79

• End-user Survey Objectives 80

• End-user Survey Methodology 81

• Outsourcing Trend Analysis by Company Type 82

• Number of CMOs Companies Work With and by Company Type 83

• End-user Classification Based on CMO Use 84

• End-user Breakdown by Company Type 85

• Criteria for CMO Selection 86

• Top 5 Factors for CMO Selection 87

• Top 5 Factors for CMO Selection Discussion 88

• Stated Versus Unstated Importance of Selection Factors 89

Page 18: Global Pharmaceutical Contract Manufacturing Market

18 NC04-52

Contents (continued)

Section Slide Number

• Stated Versus Unstated Importance of Selection Factors Discussion 90

• Extent of Outsourcing to CMOs by Service Areas 91

• Analysis of Outsourcing Budget Based on Product Revenue 92

• Outsourcing of Pharmaceutical Manufacturing Demand Forecast 93

• Industry Capacity Utilisation Forecast 94

• Industry Capacity Utilisation Forecast Discussion 95

Market Share and Competitive Analysis—Total Pharmaceutical Contract

Manufacturing Market

96

• Market Share 97

• Market Share Analysis 98

• CMO Breakdown by Finished Dose Segments 100

Solid Dose Formulations Segment Breakdown 130

• Solid Dose Formulations Segment Key Findings 131

• Market Engineering Measurements 132

• Revenue Forecast 133

• Revenue Forecast Discussion 134

Page 19: Global Pharmaceutical Contract Manufacturing Market

19 NC04-52

Contents (continued)

Section Slide Number

Liquid and Semi-solid Dose Formulations Segment Breakdown 136

• Liquid and Semi-solid Dose Formulations Segment Key Findings 137

• Market Engineering Measurements 139

• Revenue Forecast 139

• Revenue Forecast Discussion 140

Injectable Dose Formulations Segment Breakdown 141

• Injectable Dose Formulations Segment Key Findings 142

• Market Engineering Measurements 143

• Revenue Forecast 144

• Revenue Forecast Discussion 145

United States Breakdown 147

• US Pharmaceutical Contract Manufacturing Market—Market Engineering

Measurements

148

• US Pharmaceutical Contract Manufacturing Market Revenue Forecast 149

• US Pharmaceutical Contract Manufacturing Market Revenue Forecast Discussion 150

• Solid Dose Formulations Segment Revenue Forecast 151

Page 20: Global Pharmaceutical Contract Manufacturing Market

20 NC04-52

Contents (continued)

Section Slide Number

• Solid Dose Formulations Segment Revenue Forecast Discussion 152

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 153

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 154

• Injectable Dose Formulations Segment Revenue Forecast 155

• Injectable Dose Formulations Segment Revenue Forecast Discussion 156

• Pricing Analysis 157

• Market Analysis 158

• PESTLE Analysis 159

Europe Breakdown 160

• European Pharmaceutical Contract Manufacturing Market—Market Engineering

Measurements

161

• European Pharmaceutical Contract Manufacturing Market Revenue Forecast 162

• European Pharmaceutical Contract Manufacturing Market Revenue Forecast

Discussion

163

• Solid Dose Formulations Segment Revenue Forecast 164

• Solid Dose Formulations Segment Revenue Forecast Discussion 165

Page 21: Global Pharmaceutical Contract Manufacturing Market

21 NC04-52

Contents (continued)

Section Slide Number

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 166

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 167

• Injectable Dose Formulations Segment Revenue Forecast 168

• Injectable Dose Formulations Segment Revenue Forecast Discussion 169

• Pricing Analysis 170

• Market Analysis 171

• PESTLE Analysis 172

United Kingdom Breakdown 173

• Solid Dose Formulations Segment Revenue Forecast 174

• Solid Dose Formulations Segment Revenue Forecast Discussion 175

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 176

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 177

• Injectable Dose Formulations Segment Revenue Forecast 178

• Injectable Dose Formulations Segment Revenue Forecast Discussion 179

Germany Breakdown 180

• Solid Dose Formulations Segment Revenue Forecast 181

Page 22: Global Pharmaceutical Contract Manufacturing Market

22 NC04-52

Contents (continued)

Section Slide Number

• Solid Dose Formulations Segment Revenue Forecast Discussion 182

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 183

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 184

• Injectable Dose Formulations Segment Revenue Forecast 185

• Injectable Dose Formulations Segment Revenue Forecast Discussion 186

France Breakdown 187

• Solid Dose Formulations Segment Revenue Forecast 188

• Solid Dose Formulations Segment Revenue Forecast Discussion 189

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 190

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 191

• Injectable Dose Formulations Segment Revenue Forecast 192

• Injectable Dose Formulations Segment Revenue Forecast Discussion 193

Italy Breakdown 194

• Solid Dose Formulations Segment Revenue Forecast 195

• Solid Dose Formulations Segment Revenue Forecast Discussion 196

Page 23: Global Pharmaceutical Contract Manufacturing Market

23 NC04-52

Contents (continued)

Section Slide Number

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 197

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 198

• Injectable Dose Formulations Segment Revenue Forecast 199

• Injectable Dose Formulations Segment Revenue Forecast Discussion 200

Spain Breakdown 201

• Solid Dose Formulations Segment Revenue Forecast 202

• Solid Dose Formulations Segment Revenue Forecast Discussion 203

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 204

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 205

• Injectable Dose Formulations Segment Revenue Forecast 206

• Injectable Dose Formulations Segment Revenue Forecast Discussion 207

Scandinavia Breakdown 208

• Solid Dose Formulations Segment Revenue Forecast 209

• Solid Dose Formulations Segment Revenue Forecast Discussion 210

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 211

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 212

Page 24: Global Pharmaceutical Contract Manufacturing Market

24 NC04-52

Contents (continued)

Section Slide Number

• Injectable Dose Formulations Segment Revenue Forecast 213

• Injectable Dose Formulations Segment Revenue Forecast Discussion 214

Benelux Breakdown 215

• Solid Dose Formulations Segment Revenue Forecast 216

• Solid Dose Formulations Segment Revenue Forecast Discussion 217

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast 218

• Liquid and Semi-solid Dose Formulations Segment Revenue Forecast Discussion 219

• Injectable Dose Formulations Segment Revenue Forecast 220

• Injectable Dose Formulations Segment Revenue Forecast Discussion 221

Key Companies to Watch 222

• Key Companies to Watch 223

• Catalent 224

• Patheon 227

• Aenova 230

• Famar 233

• Fareva 236

Page 25: Global Pharmaceutical Contract Manufacturing Market

25 NC04-52

Contents (continued)

Section Slide Number

• Haupt Pharma AG 239

• Recipharm AB 242

• DPT Laboratories 245

• Aesica 248

• Baxter BioPharma Solutions 251

• Vetter Pharma 254

• Hospira One 2 One 257

• NextPharma Technologies 260

The Last Word 263

• The Last Word—Three Big Predictions 264

• The Last Word—Discussion 265

• Legal Disclaimer 268

Appendix 269

• Market Background 270

• Important Market Metrics 271

• Market Landscape and Pricing 272

Page 26: Global Pharmaceutical Contract Manufacturing Market

26 NC04-52

Contents (continued)

Section Slide Number

• Drivers Explained 273

• Restraints Explained 278

• US Patent Expiration Timetable 282

• Europe Patent Expiration Timetable 284

• Decision Support Database—Total Healthcare Expenditure 291

• Decision Support Database—Public Healthcare Expenditure 293

• Decision Support Database—Private Healthcare Expenditure 295

• Additional Sources of Information on Contract Outsourcing Services 297

• List of Other Key Companies Included in this Research Service 298

• Market Engineering Methodology 299

• Learn More—Next Steps 300

Page 27: Global Pharmaceutical Contract Manufacturing Market

27 NC04-52

List of Exhibits

Section Slide Number

Total Pharmaceutical Contract Manufacturing Market: Market Segmentation, Global, 2012 27

Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements,

Global, 2012

29

Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by

Segments, Global, 2012

40

Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by

Manufacturing Process, Global, 2012

41

Total Pharmaceutical Contract Manufacturing Market: Percent Sales Breakdown by Patent

Exclusivity Status, Global, 2012

42

Total Pharmaceutical Contract Manufacturing Market: Percent Revenue Breakdown by

Geographic Region, Global, 2012

43

Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2012 and

2022

44

Total Pharmaceutical Contract Manufacturing Market: Game-changing Strategies, Global,

2012

47

Total Pharmaceutical Contract Manufacturing Market: Market Outlook, Global, 2010–2012 50

Total Pharmaceutical Contract Manufacturing Market: Key Market Drivers, Global, 2013–

2017

52

Page 28: Global Pharmaceutical Contract Manufacturing Market

28 NC04-52

List of Exhibits (continued)

Section Slide Number

Total Pharmaceutical Contract Manufacturing Market: Key Market Restraints, Global,

2013–2017

53

Total Pharmaceutical Contract Manufacturing Market: Impact of Key Drivers and

Restraints, Global, 2012

54

Total Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements,

Global, 2012

57

Total Pharmaceutical Contract Manufacturing Market: Revenue Forecast, Global, 2009–2017 59

Total Pharmaceutical Contract Manufacturing Market: Percent Points Comparison with the US,

Global, 2012

61

Total Pharmaceutical Contract Manufacturing Market: Percent Points Manufacturing Cost

Comparison with the US, Global, 2012

62

Total Pharmaceutical Contract Manufacturing Market: Percent Points Labour Cost Comparison

with the US, Global, 2012

62

Total Pharmaceutical Contract Manufacturing Market: Percent Revenue Forecast by Region,

Global, 2009–2017

63

Total Pharmaceutical Contract Manufacturing Market: Revenue Forecast by Region, Global,

2009–2017

64

Total Pharmaceutical Market: Combined Prescription Sales for the Top 50 Pharmaceutical

Companies by Molecule Type, Global, 2012–2017

65

Page 29: Global Pharmaceutical Contract Manufacturing Market

29 NC04-52

Section Slide Number

Total Pharmaceutical Market: Combined Prescription Sales for the Top 50 Pharmaceutical

Companies by Therapeutic Area, Global, 2012–2017

66

Pharmaceutical Contract Manufacturing Market: Percent of Combined Prescription Sales for Big

Pharmaceutical Companies by Molecule Type, Global, 2012–2017

67

Pharmaceutical Contract Manufacturing Market: Percent of Combined Prescription Sales for Mid-

sized Pharmaceutical Companies by Molecule Type, Global, 2012–2017

68

Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Activities

Outsourced, Global, 2012

70

Total Pharmaceutical Contract Manufacturing Market: CAGRs of Segments Likely to Have

Higher Levels of Outsourcing, Global, 2012–2019

70

Total Pharmaceutical Contract Manufacturing Market: Market Impact of Key Trends, Global, 2012 76

Total Pharmaceutical Contract Manufacturing Market: Segment Lifecycle Analysis, Global, 2012 78

Total Pharmaceutical Contract Manufacturing Market: Percent Finished Dose Manufacturing

Outsourced by Company Type, Global, 2012

82

Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Number of CMOs

Companies Work With, Global, 2012

83

Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Number of CMOs

Companies Work With by Company Type, Global, 2012

83

List of Exhibits (continued)

Page 30: Global Pharmaceutical Contract Manufacturing Market

30 NC04-52

List of Exhibits (continued)

Section Slide Number

Total Pharmaceutical Contract Manufacturing Market: End-user Percent Breakdown by CMO

Budget, Global, 2012

84

Total Pharmaceutical Contract Manufacturing Market: End-user Percent Breakdown by Company

Type, Global, 2012

85

Total Pharmaceutical Contract Manufacturing Market: Customer Utility Value of Various Factors

Involved in the Selection of a CMO, Global, 2012

86

Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Top 5 Factors for

CMO Selection, Global, 2012

87

Total Pharmaceutical Contract Manufacturing Market: Percent Breakdown of Top 5 Factors for

CMO Selection by Company Type, Global, 2012

88

Total Pharmaceutical Contract Manufacturing Market: Extent of Outsourcing to CMOs by Service

Areas, Global, 2012

91

Total Pharmaceutical Contract Manufacturing Market: Extent of Outsourcing to CMOs by Service

Areas, Global, 2017

91

Total Pharmaceutical Contract Manufacturing Market: Percent Outsourcing Budget Allocation

Based on Product Revenue, Global, 2012

92

Total Pharmaceutical Contract Manufacturing Market: Outsourcing of Pharmaceutical

Manufacturing Demand Forecast, Global, 2012–2017

93

Total Pharmaceutical Contract Manufacturing Market: Industry Capacity Utilization Forecast,

Global, 2012–2017

94

Page 31: Global Pharmaceutical Contract Manufacturing Market

31 NC04-52

List of Exhibits (continued)

Section Slide Number

Total Pharmaceutical Contract Manufacturing Market: CMO Market Share, Global, 2012 97

Total Pharmaceutical Contract Manufacturing Market: CMO Market Share Analysis, Global, 2012 98

Total Pharmaceutical Contract Manufacturing Market: CMO Breakdown by Finished Dose

Segments, Global, 2012

100

Solid Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global, 2012 131

Solid Dose Formulations Segment: Market Engineering Measurements, Global, 2012 132

Solid Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 133

Liquid and Semi-solid Dose Formulations Segment: Percent Sales Breakdown by Sub-segments,

Global, 2012

137

Liquid and Semi-solid Dose Formulations Segment: Market Engineering Measurements, Global,

2012

138

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 139

Injectable Dose Formulations Segment: Percent Sales Breakdown by Sub-segments, Global,

2012

142

Injectable Dose Formulations Segment: Market Engineering Measurements, Global, 2012 143

Injectable Dose Formulations Segment: Revenue Forecast, Global, 2009–2017 144

Page 32: Global Pharmaceutical Contract Manufacturing Market

32 NC04-52

List of Exhibits (continued)

Section Slide Number

Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, US, 2012 148

Pharmaceutical Contract Manufacturing Market: Revenue Forecast, US, 2009–2017 149

Solid Dose Formulations Segment: Revenue Forecast, US, 2009–2017 151

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, US, 2009–2017 153

Injectable Dose Formulations Segment: Revenue Forecast, US, 2009–2017 156

Pharmaceutical Contract Manufacturing Market: Pricing Analysis, US, 2012 157

Pharmaceutical Contract Manufacturing Market: PESTLE Analysis, US, 2012 159

Pharmaceutical Contract Manufacturing Market: Market Engineering Measurements, Europe,

2012

161

Pharmaceutical Contract Manufacturing Market: Revenue Forecast, Europe, 2009–2017 162

Solid Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 164

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 166

Injectable Dose Formulations Segment: Revenue Forecast, Europe, 2009–2017 168

Pharmaceutical Contract Manufacturing Market: Pricing Analysis, Europe, 2012 170

Pharmaceutical Contract Manufacturing Market: PESTLE Analysis, Europe, 2012 172

Page 33: Global Pharmaceutical Contract Manufacturing Market

33 NC04-52

List of Exhibits (continued)

Section Slide Number

Solid Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–2017 174

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–

2017

176

Injectable Dose Formulations Segment: Revenue Forecast, United Kingdom, 2009–2017 178

Solid Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 181

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 183

Injectable Dose Formulations Segment: Revenue Forecast, Germany, 2009–2017 185

Solid Dose Formulations Segment: Revenue Forecast, France, 2009–2017 188

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, France, 2009–2017 190

Injectable Dose Formulations Segment: Revenue Forecast, France, 2009–2017 192

Solid Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 195

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 197

Injectable Dose Formulations Segment: Revenue Forecast, Italy, 2009–2017 199

Solid Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 202

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 204

Page 34: Global Pharmaceutical Contract Manufacturing Market

34 NC04-52

List of Exhibits (continued)

Section Slide Number

Injectable Dose Formulations Segment: Revenue Forecast, Spain, 2009–2017 206

Solid Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 209

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 211

Injectable Dose Formulations Segment: Revenue Forecast, Scandinavia, 2009–2017 213

Solid Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 216

Liquid and Semi-solid Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 218

Injectable Dose Formulations Segment: Revenue Forecast, Benelux, 2009–2017 220

Total Pharmaceutical Contract Manufacturing Market: Important Market Growth Metrics, Global,

2012

271

Total Pharmaceutical Contract Manufacturing Market: Client-wise Revenue Contribution to CMOs,

Global, 2012

274

Total Pharmaceutical Contract Manufacturing Market: VC Investment in Pharmaceutical/Biotech

Companies and CMOs, Global, 2000–2011

280

Total Pharmaceutical Contract Manufacturing Market: Key Blockbuster Drugs Losing Patent

Protection, US, 2012–2017

282

Total Pharmaceutical Contract Manufacturing Market: Key Blockbuster Drugs Losing Patent

Protection, Europe, 2010–2017

284

Page 35: Global Pharmaceutical Contract Manufacturing Market

35 NC04-52

List of Exhibits (continued)

Section Slide Number

Decision Support Database: Total Healthcare Expenditure, Global, 2008-2018 291

Decision Support Database: Public Healthcare Expenditure, Global, 2008-2018 293

Decision Support Database: Private Healthcare Expenditure, Global, 2008-2018 295

Page 36: Global Pharmaceutical Contract Manufacturing Market

36 NC04-52

For more information

Jennifer Carson

Healthcare & Life Sciences

(+1) 210.247.2450

[email protected]


Recommended